A substantial part of Loma Therapeutics’ pre-clinical proof of concept was published in Cancer Immunology Research. Briefly, the HPV-targeted immunotherapy underwent thorough in vitro QC to ensure expression of HPV genes and successful inactivation of E6 and E7...